好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Natural History of Afferent Baroreflex Failure in Adults
Neuromuscular and Clinical Neurophysiology (EMG)
Autonomic Disorders Posters (7:00 AM-5:00 PM)
003

The baroreflex normally serves to buffer blood pressure against excessive fluctuations. ABF occurs when afferent glossopharyngeal and vagal nerve fibers or their central connections are impaired. ABF is characterized clinically by labile hypertension, episodic tachycardia, and orthostatic hypotension (OH). ABF is rare, but analysis of data from a large referral center for autonomic disorders may allow a better understanding of this syndrome.

To describe the natural history of afferent baroreflex failure (ABF)

We performed a retrospective chart review of all patients who underwent standardized autonomic reflex testing between 2000 and 2020 and had confirmation of the diagnosis of ABF by an autonomic disorders specialist.

A total of 104 patients with ABF were identified. Head and neck radiation was the most common etiology (86.5%) followed by neck surgery (5.8%) and other causes (7.7%). The most common findings were hypertension (87.5%), blood pressure lability (78.8%), OH (91.3%), syncope (58.6%), headache (22.1%), and tachycardia (20.2%). Patients commonly were treated with antihypertensives (66.3%), pressors (41.3%), or both (19.2%). In ABF due to radiation, median latency to symptom onset  was 7.2 years, while in ABF due to surgery, symptoms of ABF started shortly after surgery (median = 0 year [0-2]). Patients with radiation-induced ABF frequently had other radiation-induced complications, including dysphagia (67.8%), hypothyroidism (65.5%), brachial plexopathy (20%), cranial neuropathy (36.6%), and stroke (22.2%). All-cause mortality was 39.4% over a 20-year period.

ABF should be suspected in patients with history of head and neck cancer treated by radiation and/or surgery who present with labile hypertension and OH. The management is challenging and may require the use of both antihypertensive and pressor medications. Patients with radiation-induced ABF often experience multiple other complications of radiation. Further studies are needed to better understand the pathophysiology of ABF.

Authors/Disclosures
Guillaume Lamotte, MD
PRESENTER
Dr. Lamotte has nothing to disclose.
Elizabeth A. Coon, MD, FAAN (Mayo Clinic) Dr. Coon has nothing to disclose.
Mariana Suarez No disclosure on file
Paola Sandroni, MD, PhD, FAAN (Mayo Clinic) Dr. Sandroni has nothing to disclose.
Eduardo E. Benarroch, MD, FAAN (Mayo Clinic) Dr. Benarroch has nothing to disclose.
Jeremy K. Cutsforth-Gregory, MD, FAAN (Mayo Clinic) Dr. Cutsforth-Gregory has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Cutsforth-Gregory has received publishing royalties from a publication relating to health care.
Michelle L. Mauermann, MD, FAAN (Mayo Clinic) The institution of Dr. Mauermann has received research support from IONIS. The institution of Dr. Mauermann has received research support from Alnylam. Dr. Mauermann has received publishing royalties from a publication relating to health care.
Sarah E. Berini, MD (Mayo Clinic) Dr. Berini has nothing to disclose.
Kamal Shouman, MD (Mayo Clinic) Dr. Shouman has nothing to disclose.
David M. Sletten, MBA (Mayo Clinic) Mr. Sletten has nothing to disclose.
Brent P. Goodman, MD (Dept of Neuro /Mayo Clinic) Dr. Goodman has nothing to disclose.
Phillip A. Low, MD, FAAN (Mayo Clinic) Dr. Low has nothing to disclose.
Wolfgang Singer, MD, FAAN (Mayo Clinic) Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UniQure. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. The institution of Dr. Singer has received research support from NIH. The institution of Dr. Singer has received research support from FDA. The institution of Dr. Singer has received research support from Michael J. Fox Foundation. Dr. Singer has received intellectual property interests from a discovery or technology relating to health care.